NCT03896646View on ClinicalTrials.gov

Radioembolization for HCC Patients With Personalized Yttrium-90 Dosimetry for Curative Intent (RAPY90D)

NAActive, not recruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

October 10, 2019

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2026

Conditions
Stage III Hepatocellular Carcinoma AJCC v8Stage IIIA Hepatocellular Carcinoma AJCC v8Stage IIIB Hepatocellular Carcinoma AJCC v8Stage IV Hepatocellular Carcinoma AJCC v8Stage IVA Hepatocellular Carcinoma AJCC v8Stage IVB Hepatocellular Carcinoma AJCC v8Unresectable Hepatocellular Carcinoma
Interventions
PROCEDURE

Computed Tomography

Undergo SPECT/CT HIDA scan

OTHER

Hepatobiliary Iminodiacetic Acid Scan

Undergo SPECT/CT HIDA scan

PROCEDURE

Single Photon Emission Computed Tomography

Undergo SPECT/CT HIDA scan

RADIATION

Yttrium Y 90 Glass Microspheres

Undergo radioembolization with yttrium Y 90 glass microspheres

PROCEDURE

Yttrium-90 Microsphere Radioembolization

Undergo yttrium-90 microsphere radioembolization

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER